IGF-1 LR3 FAQ for Laboratory Researchers
This comprehensive IGF-1 LR3 FAQ serves as an essential reference for principal investigators, laboratory managers, and research personnel evaluating Long Arginine 3 Insulin-like Growth Factor 1. Designed strictly for in vitro and preclinical research applications, this technical guide addresses chemical structure, receptor binding dynamics, reconstitution parameters, analytical verification, and handling protocols.
Quick answer
This comprehensive IGF-1 LR3 FAQ serves as an essential reference for principal investigators, laboratory managers, and research personnel evaluating Long Arginine 3 Insulin-like Growth Factor 1. Designed strictly for in vitro and preclinical research applications, this technical guide addresses chemical structure, receptor binding dynamics, reconstitution parameters, analytical verification, and handling protocols.
Key takeaways
- Long Arginine 3 Insulin-like Growth Factor 1 ([IGF-1 LR3](/research-peptides/igf-1-lr3)) is a synthetically modified analog of endogenous human insulin-like growth factor 1.
- Preclinical studies indicate that [IGF-1 LR3](/research-peptides/igf-1-lr3) operates via activation of the receptor tyrosine kinase IGF-1R, initiating autophosphorylation of intracellular domain residues.
- Maintaining high analytical rigor in growth factor research requires accurate determination of peptide purity, identity, and structural integrity.
- Bacterial endotoxins (lipopolysaccharides, or LPS) present a significant confounding variable in cell culture and tissue-based assays.
Molecular Architecture and Structural Modifications
Long Arginine 3 Insulin-like Growth Factor 1 (IGF-1 LR3) is a synthetically modified analog of endogenous human insulin-like growth factor 1. While wild-type IGF-1 consists of a 70-amino-acid single-chain polypeptide, IGF-1 LR3 incorporates two distinct structural alterations that significantly alter its pharmacokinetic profile in experimental settings. First, a substitution of glutamic acid (Glu) with arginine (Arg) occurs at position 3 of the native sequence. Second, a 13-amino-acid peptide extension is added to the N-terminus, resulting in a total sequence length of 83 amino acids and a molecular weight of approximately 9,111 Da.
In cell culture models and tissue preparations, these structural alterations maintain high-affinity binding to the type 1 IGF receptor (IGF-1R) while drastically reducing the compound's affinity for insulin-like growth factor binding proteins (IGFBPs). Under physiological and baseline assay conditions, endogenous IGF-1 is rapidly sequestered by six primary binding proteins (IGFBP-1 through IGFBP-6), which regulate its bioavailability and limit its biological half-life. By evading IGFBP binding, IGF-1 LR3 remains unattached in aqueous assay media, increasing the fraction of unbound peptide available to engage cell-surface receptors over extended observational windows.
Receptor Binding Kinetics and Signal Transduction
Preclinical studies indicate that IGF-1 LR3 operates via activation of the receptor tyrosine kinase IGF-1R, initiating autophosphorylation of intracellular domain residues. This phosphorylation event recruits insulin receptor substrate (IRS) proteins, activating two primary downstream intracellular signaling cascades: the Phosphoinositide 3-kinase (PI3K)-Akt pathway and the Mitogen-Activated Protein Kinase (MAPK/ERK) pathway. In vitro assays evaluating cellular proliferation, protein synthesis, and metabolic transport utilize IGF-1 LR3 to stimulate these target pathways without the inhibitory buffering effects typical of native growth factors.
Because of its diminished affinity for IGFBPs, the relative potency of IGF-1 LR3 in cell-based assays is reported to be substantially higher than that of native IGF-1. In vitro research demonstrates that lower molar concentrations of IGF-1 LR3 are required to achieve maximal receptor autophosphorylation and downstream transcriptional activation compared to unmodified growth factors. Investigators utilizing this molecule in cell culture experiments must calibrate working concentrations carefully to account for this enhanced baseline bioactivity.
Analytical Verification: HPLC and Mass Spectrometry
Maintaining high analytical rigor in growth factor research requires accurate determination of peptide purity, identity, and structural integrity. PX1 Research subjects every synthesis lot of research peptides to rigorous analytical testing in ISO 17025 accredited laboratories. High-Performance Liquid Chromatography (HPLC) is conducted using reverse-phase columns to separate and quantify the target peptide from related synthesis impurities, truncated sequences, or oxidation byproducts, ensuring a minimum purity threshold of 98%.
Identity verification is performed using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) or Electrospray Ionization Mass Spectrometry (ESI-MS). Mass spectrometry confirms the exact molecular mass of the 83-amino-acid chain, verifying the presence of the N-terminal extension and the Arg3 substitution. Researchers can access lot-specific Certificates of Analysis (COA) directly through PX1 Research, providing full transparency regarding chromatographic purity profiles and mass spectrum data prior to experimental deployment.
Endotoxin Qualification and Cell Culture Safety
Bacterial endotoxins (lipopolysaccharides, or LPS) present a significant confounding variable in cell culture and tissue-based assays. Presence of trace endotoxins can trigger innate immune signaling, alter cellular metabolism, activate toll-like receptor 4 (TLR4), and cause premature cell death, invalidating experimental outcomes. For this reason, high-grade reagents intended for sensitive bioassays must undergo stringent endotoxin testing using the Limulus Amebocyte Lysate (LAL) assay or recombinant Factor C methods.
PX1 Research enforces strict endotoxin specifications (<0.01 EU/µg) for all growth factors and signaling analogs. Every batch manufactured in our USA-synthesized, GMP-compliant facilities undergoes kinetic chromogenic LAL analysis to ensure endotoxin levels remain below detection limits. This rigorous quality control ensures that observed cell line responses—such as changes in gene expression, proliferation rates, or protein translation—are directly attributable to IGF-1 LR3 receptor interaction rather than contaminant-mediated cellular stress.
Reconstitution Protocols for Laboratory Investigation
Proper reconstitution is critical to maintain the secondary structure and biological activity of lyophilized IGF-1 LR3. The peptide is typically supplied as a sterile, lyophilized cake containing target mass (e.g., 1 mg). Because basic or neutral pH solutions can lead to peptide aggregation or precipitation over time, reconstitution of IGF-1 LR3 requires an acidic diluent for initial solubilization. The standard protocol involves reconstituting the dry powder in sterile 10 mM to 100 mM acetic acid (pH 2.5 to 3.0) to yield a concentrated stock solution (typically 1.0 mg/mL).
Once fully dissolved in dilute acetic acid, the stock solution can be further diluted into neutral pH laboratory buffers, such as Phosphate-Buffered Saline (PBS) or cell culture media containing 0.1% Bovine Serum Albumin (BSA) or human serum albumin as a carrier protein. Carrier proteins prevent non-specific binding of the hydrophobic peptide to polypropylene vial walls and microfluidic tubing. Detailed procedures and solvent suitability charts can be found in our comprehensive peptide reconstitution guide.
Thermal Stability and Storage Guidelines
Lyophilized IGF-1 LR3 exhibits robust stability when stored under appropriate environmental conditions. In its dry state, the product should be kept at -20°C for short-to-medium term storage, or at -80°C for extended preservation exceeding 12 months. Exposure to ambient room temperature during transit is acceptable for short intervals, but lyophilized vials should be placed in sub-zero storage immediately upon receipt in the laboratory.
Once reconstituted in an acidic buffer, working aliquots should be stored at -20°C or -80°C to prevent enzymatic degradation and peptide cleavage. Repeated freeze-thaw cycles must be strictly avoided, as the formation of ice crystals can disrupt non-covalent interactions and induce protein denaturation or aggregation. Researchers should aliquot reconstituted solutions into single-use microcentrifuge tubes prior to freezing. Reconstituted solutions containing carrier protein stored at 2°C to 8°C remain stable for up to 7 to 14 days, provided sterile technique is maintained.
Comparative Analysis: IGF-1 Analog Comparison
When designing experiments involving growth factor signaling pathways, investigators often evaluate several related compounds within the insulin-like growth factor superfamily. Choosing the appropriate research tool depends heavily on the desired receptor kinetics, stability profiles, and assay duration required by the experimental model.
Compared to native human growth factors, synthetic analogs offer distinct bio-availability profiles. While native IGF-1 exhibits a short biological half-life due to rapid sequestration by binding proteins, IGF-1 DES—a truncated analog lacking the first three N-terminal amino acids—demonstrates minimal IGFBP binding and enhanced potency specifically in localized cellular environments. Conversely, IGF-1 LR3 provides both reduced binding protein affinity and extended operational stability in cell culture media. For broader studies involving the growth hormone signaling axis, researchers may also contrast these direct growth factors with upstream secretagogues like CJC-1295 to examine systemic versus localized signaling cascades.
PX1 Research Manufacturing and Sourcing Integrity
Reliable research outcomes depend upon batch-to-batch consistency and verifiable compound provenance. PX1 Research synthesizes peptides in state-of-the-art facilities located within the United States under strict quality control standards. Each step of the solid-phase peptide synthesis (SPPS) process is closely monitored to ensure correct sequence fidelity, complete deprotection, and high-yield cleavage.
To support high-throughput screening and long-term academic or commercial research projects, PX1 Research offers flexible ordering options, including wholesale bulk ordering for institution-wide procurement. Orders are fulfilled directly from our California and Arizona logistics hubs, featuring same-day shipping for orders placed Monday through Friday before cut-off times. Every shipment is packaged with temperature-protective cold packs to guarantee product stability throughout transit.
Frequently Asked Questions
What is the sequence and molecular weight of IGF-1 LR3?
IGF-1 LR3 is an 83-amino-acid synthetic peptide comprising the native 70-amino-acid IGF-1 sequence, a substitution of Glutamic Acid with Arginine at position 3, and a 13-amino-acid N-terminal extension (MFPAMPLSSLFVN). Its calculated molecular weight is approximately 9,111 Da.
Why is IGF-1 LR3 preferred over native IGF-1 in cell culture experiments?
In vitro studies indicate that native IGF-1 is rapidly bound and neutralized by endogenous IGF-binding proteins (IGFBPs) present in serum-supplemented media. IGF-1 LR3 has significantly lower affinity for these binding proteins, allowing higher concentrations of free, active peptide to engage the IGF-1R receptor over prolonged durations.
How does PX1 Research verify the purity and identity of IGF-1 LR3?
PX1 Research verifies every batch through high-performance liquid chromatography (HPLC) for purity analysis (guaranteed >98%) and mass spectrometry (MALDI-TOF or ESI-MS) for sequence and molecular mass confirmation. Quality assurance documentation is performed by ISO 17025 accredited analytical laboratories.
What solvent is recommended for reconstituting lyophilized IGF-1 LR3?
Lyophilized IGF-1 LR3 should be reconstituted initially in sterile 10 mM to 100 mM acetic acid (pH 2.5–3.0) to ensure complete dissolution. Once solubilized, it can be diluted into working buffers such as PBS containing 0.1% BSA as a carrier protein.
How should reconstituted IGF-1 LR3 be stored in the lab?
Reconstituted stock solutions should be divided into single-use aliquots and stored at -20°C or -80°C. Aliquots containing carrier protein remain stable at 2–8°C for 7 to 14 days. Avoid repeated freeze-thaw cycles to prevent protein denaturation.
What are the endotoxin limits for PX1 Research IGF-1 LR3?
PX1 Research enforces strict endotoxin controls, specifying levels below 0.01 EU/µg as determined by LAL kinetic chromogenic assays. This prevents endotoxin-induced cell stress in sensitive in vitro cultures.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are USA-synthesized in GMP-compliant facilities. Orders are fulfilled and shipped directly from our primary distribution hubs in California and Arizona with same-day dispatch available Monday through Friday.
How does IGF-1 LR3 differ structurally from IGF-1 DES?
IGF-1 LR3 contains an added 13-amino-acid N-terminal extension and an Arg3 substitution (83 amino acids total), whereas IGF-1 DES is a truncated variant lacking the first three N-terminal amino acids (67 amino acids total). Both exhibit reduced binding protein affinity through different structural modifications.
Is a Certificate of Analysis (COA) provided with every lot?
Yes. Every lot of IGF-1 LR3 supplied by PX1 Research includes a comprehensive, lot-specific COA detailing HPLC purity traces, mass spectrometry spectra, and endotoxin assay results.
Why is a carrier protein like BSA recommended in working solutions?
At low working concentrations (e.g., nanogram levels), hydrophobic peptides like IGF-1 LR3 readily stick to glass and polypropylene surfaces. Adding 0.1% BSA or human serum albumin acts as a blocking agent to prevent non-specific adsorption.
What receptor targets does IGF-1 LR3 interact with in vitro?
Preclinical data show that IGF-1 LR3 binds primarily to the IGF-1 receptor (IGF-1R) and, to a lesser extent, insulin/IGF-1 hybrid receptors, activating downstream PI3K/Akt and MAPK signaling pathways.
Can PX1 Research fulfill bulk or commercial laboratory orders for IGF-1 LR3?
Yes. PX1 Research provides custom scale-up and bulk procurement services through our wholesale portal, offering standardized batching and dedicated analytical documentation for high-volume laboratory requirements.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.